Chikungunya (Protinhi)(Chikungunya (Protinhi)) - 药物靶点：Protease_在研适应症：基孔肯雅热_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点

Protease

作用机制

蛋白酶抑制剂

治疗领域

感染其他疾病

在研适应症

基孔肯雅热

非在研适应症-

原研机构

Protinhi BV

在研机构

Protinhi BV

非在研机构-

最高研发阶段临床前

首次获批日期-

最高研发阶段(中国)-

特殊审评-

关联

2

项与 Chikungunya (Protinhi) 相关的临床试验

TCTR20240812007 / Not yet recruiting临床3期

A Phase 3b Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of an Adjuvanted Chikungunya Virus Virus-like Particle (CHIKV VLP) Vaccine for the Prevention of Chikungunya Disease in Adolescents (12 to 18 Years) and Adults (18 Years or more than)

开始日期2024-12-12

申办/合作机构

Bavarian Nordic A/S

CTRI/2021/02/031160 / Completed临床1期

A Phase I Randomized Single Blind Placebo Controlled Study to Evaluate the Safety and Immunogenicity of Chikungunya Vaccine (Inactivated) of HBI when administered by two different dosage schedules to Healthy Subjects of 19 to 49 Years of age.

开始日期2021-02-15

申办/合作机构